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b-Adrenergic receptor blockers or b-blockers represent one of the
oldest classes of cardiovascular agents and have been considered a
cornerstone therapy for hypertension and heart disease for the past 5
decades. They are advocated as a ﬁrst-line treatment for uncompli-
cated essential hypertension in patients younger than 60 years of age
as recommended by the Canadian Hypertension Education Program.
However, despite the well-established antihypertensive and cardio-
vascular beneﬁts of b-blockers, a number of studies argue that they
might not have the same clinical advantages of other classes of agents
in terms of morbidity/mortality outcomes. This review will focus on the
heterogeneity of the pharmacologic characteristics of b-blockers, and
we will discuss the metabolic and hemodynamic differences within the
b-blocker class and try to assess the potential implications of these
differences for optimal selection in hypertension.Received for publication August 16, 2013. Accepted December 1, 2013.
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ORESUME
Les bloqueurs des recepteurs b-adrenergiques ou b-bloqueurs
representent l’une des plus anciennes classes d’agents cardiovascu-
laires et ont ete consideres comme etant la pierre angulaire du
traitement de l’hypertension et de la cardiopathie au cours des 5
dernières decennies. Ils sont recommandes par le Programme
educatif canadien sur l’hypertension comme traitement de première
intention de l’hypertension essentielle non compliquee chez les pa-
tients de moins de 60 ans. Cependant, en depit des avantages bien
etablis des b-bloqueurs contre l’hypertension et les maladies car-
diovasculaires, de nombreuses etudes soutiennent qu’ils pourraient ne
pas avoir les mêmes avantages cliniques que les autres classes
d’agents en matière de resultats sur la morbidite et la mortalite. Cette
revue mettra l’accent sur l’heterogeneite des caracteristiques phar-
macologiques des b-bloqueurs. De plus, nous discuterons des differ-
ences metaboliques et hemodynamiques au sein de la classe des
b-bloqueurs, et essaierons d’evaluer les implications potentielles de ces
differences pour realiser une selection optimale lors d’hypertension.b-blockers represent one of the oldest classes of cardiovascular
agents and have been considered a cornerstone therapy in
heart disease such as heart failure1 and acute myocardial
infarction (MI).2 They are indicated for uncomplicated
essential hypertension in patients younger than 60 years of
age.3 Despite the well established antihypertensive beneﬁts of
b-blockers, some argue that they might not have the same
clinical advantages of other classes of agents in terms of
morbidity/mortality outcomes in patients with hyperten-
sion.4,5 b-blockers represent a heterogeneous group of agents
possessing several pharmacological properties that differentiate
them and this might have a signiﬁcant effect on clinical end
points. In addition, these properties might inﬂuence their
tolerability and adherence proﬁle that frequently limit theiruse in clinical practice.6-9 For the clinician and for the patient,
adherence is quite important because adherence is a key
element in chronic disorders such as hypertension and coro-
nary artery disease (CAD).10 The role of b-blockers in hy-
pertension has been challenged by recent meta-analyses that
found that stroke reduction might not be optimal when
compared with other classes of antihypertensive agents.4,5,11
In this article, the efﬁcacy of b-blockers will be discussed,
with a focus on the different pharmacologic characteristics. In
addition, as discussed in a previous article,12 the authors will
discuss the potential clinical implications of these differences
important for the clinician prescribing them.Mechanism of Action
b-blockers reduce sympathetic nervous system activity
through blockade of adrenergic receptor subtypes, particularly
b1, b2, and b3. b1 receptors are primarily in the heart and
some of the beneﬁcial effects of blockade include bradycardia
and improved diastolic coronary ﬁlling time, reduced oxygen
requirements, and a reduction of renin, all beneﬁcial in heart
failure and myocardial ischemia. b2 receptors are mostlypen access under CC BY-NC-ND license.
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tree and stimulation leads to dilation. b3 receptors are located
in adipocytes and the heart, and blockade by nonselective
agents might contribute to their weight-increase and meta-
bolic effects.13 b-blocker speciﬁcity refers to the drugs’ greater
afﬁnity for b1 receptors over b2 at usual drug levels, and
therefore speciﬁcity for cardiac effects, and nonspeciﬁc agents
that also block b2 receptors reduce antihypertensive activity.14
Since the work of Raymond Ahlquist15 and James Black,16
many different b-blockers with distinct pharmacologic and
hemodynamic properties were developed (Table 1). A total of
12 orally administered b-blockers are currently available in
Canada. The second-generation b-blockers (atenolol, biso-
prolol, etc) were developed with a higher afﬁnity for the b1
receptor and are called cardioselective b-blockers. Blood
pressure (BP) reduction for these more traditional ﬁrst- and
second-generation b-blockers might be achieved through a
reduction in cardiac output, through heart rate and contrac-
tility reduction, but no beneﬁcial effect or even an increase in
peripheral vascular resistance.20 The third generation
b-blockers (carvedilol, labetalol, nebivolol) have vasodilating
properties mediated by a-adrenoreceptor blockade and/or
through nitric oxide (NO) release.21 They reduce BP by
decreasing peripheral vascular resistance while maintaining or
increasing cardiac output.21 Finally, b-blockers also differ in
other pharmacologic characteristics such as lipophilicity and
intrinsic sympathetic activity (ISA).Efﬁcacy of b-Blockers as a Monolithic Class
Hypertension
There is a misconception that this class of agents might not
lower BP equivalently to other classes of antihypertensive
agents. A meta-analysis published by the Blood Pressure
Treatment Trialists’ Collaboration22 involving 37,872 pa-
tients and comparing different classes of antihypertensive
agents (angiotensin-converting enzyme inhibitors, calcium
channel blockers, b-blockers and/or diuretics) has shown that
differences in outcomes were minimal on a 2- to 8-year
follow-up duration for the same BP-lowering. Some have
also questioned the efﬁcacy of b-blockers in terms of hard end
points, especially on stroke prevention, when compared withTable 1. Pharmacological properties of the different b-blockers
Drug b1-Blockade potency ratio b1/b2 selectivity ISA Li
Nadolol 1.0 0 0 Lo
Pindolol 6.0 0 þþ H
Propranolol 1.0 0 0 H
Sotalol 0.3 0 0 Lo
Timolol 0.6 0 0 H
Acebutolol 0.3 þ þ M
Atenolol 1.0 þ 0 Lo
Bisoprolol 10.0 þþ 0 M
Metoprolol 1.0 þþ 0 H
Labetolol 0.3 þ 0 Lo
Carvedilol 10.0 0 0 M
Nebivolol 10.0 þþþ 0 M
0, absent; þ, low; þþ, moderate; þþþ, strong; ISA, intrinsic sympathetic acti
Adapted from Manrique et al.,17 Frishman and Saunders,18 and Mason et al.19other classes of antihypertensive agents (see Khan et al., in this
issue of the Canadian Journal of Cardiology23). Khan and
McAlister published a meta-analysis in 2006 on 145,811
patients from 21 hypertension trials.24 Their results showed
that, in placebo-controlled trials and active comparator
studies, b-blockers reduced major cardiovascular outcomes in
younger patients but not in older patients, with the excess risk
being particularly marked for stroke. It has been shown that
the nonvasodilating b-blockers, such as atenolol, lower BP by
reducing cardiac output while systemic vascular resistance
remains unchanged or actually increases, simulating the effect
of aging.25 In elderly individuals, low cardiac output and
increased peripheral resistance due to noncompliant arteries
typically characterize their hemodynamic proﬁle.26 In younger
patients, particularly linked to obesity and the metabolic
syndrome, greater sympathetic activity leads to an increase in
cardiac output and heart rate and increased peripheral vascular
resistance, in part due to endothelial dysfunction. In this
setting, a b-blocker with vasodilating properties might lead to
a correction of these pathological changes.25 Consequently, in
light of these data, the Canadian Hypertension Education
Program still recommends that b-blockers be used as the
initial therapy for hypertension in uncomplicated patients
younger than 60 years of age.3Angina and MI
b-blockers remain the standard of care for patients with
CAD, particularly for those having experienced an acute MI.27
Beneﬁts of b-blockers on cardiovascular outcomes seem to be
in direct relation to b1-receptor blockade and not on the
selectivity because atenolol and metoprolol have shown similar
results on mortality in patients who have had an MI.17 Indeed,
b-blockers decrease the work of the heart by reducing heart
rate, contractility, and systolic BP. For example, a chart review
study of more than 69,000 patients treated with b-blockers
after an MI has demonstrated that b-blockers were associated
with a 40% improvement in survival and that b-blocker sub-
type had little inﬂuence on mortality28; the different subtypes
of b-blockers all demonstrated signiﬁcant reductions in mor-
tality.29,30 However, b-blockers with ISA have been associated
with reduced clinical beneﬁts in patients who have had a recent
MI.31 The role of b-blockers in patients with coronary riskpophilicity Half-life (hours) Other
w 12-24
igh 3-4
igh 3-4
w 12 Antiarrythmic effects
igh 4-5
oderate 3-4
w 6-9
oderate 9-12
igh 3-4
w 3-4 a1-Blocking effect, direct b-
vasodilation
oderate 7-10 a1-Blocking effect
oderate 8-27 Endothelium-dependent, NO-
mediated vasodilation
vity; NO, nitric oxide.
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analysis, regrouping 44,708 patients from the Reduction of
Atherothrombosis for Continued Health (REACH) Registry,
demonstrated that b-blockers were not associated with a lower
risk of the composite cardiovascular event after a 44-month
median follow-up.27 However, in patients with an MI
within 1 year of enrollment to the study, the use of b-blockers
was associated with an improvement of the secondary outcome
(cardiovascular death, nonfatal MI, nonfatal stroke, and hos-
pitalization for atherothrombotic events).27
Heart failure
Patients with heart failure in whom there is no contrain-
dication should receive a b-blocker on a background of
angiotensin-converting enzyme-inhibition. These agents act
by decreasing sympathetic nervous system activation and
thereby improve morbidity and mortality outcomes. In this
regard, results from major studies involving bisoprolol,32
carvedilol,33 and metoprolol34 have demonstrated signiﬁcant
morbidity and mortality beneﬁts, with a mortality reduction
of approximately 35% across trials.35 In Canada, only these 3
b-blockers possess the indication in heart failure. In heart
failure, the degree of ISA impairs efﬁcacy with bisoprolol,
carvedilol and metoprolol having no ISA. When carvedilol was
compared with metoprolol in patients with chonic heart
failure in the Carvedilol Or Metoprolol European Trial
(COMET), carvedilol was found to be superior.36 Similarly,
carvedilol was found to reduce hospitalization for heart failure
or death in the Multicenter Automatic Deﬁbrillator Implan-
tation Trial with Cardiac Resynchronization Therapy
(MADIT-CRT) study.37 Interestingly, in the Beta-blocker
Evaluation of Survival Trial (BEST) trial, bucindolol, a
nonselective b-blocker with weak a-blocking properties, also
reduced hospitalization for heart failure.38 However, all-cause
mortality was signiﬁcantly reduced by 23%, but only in pa-
tients who had a systolic BP > 120 mm Hg.38 The Study of
the Effects of Nebivolol Intervention on Outcomes and
Rehospitalisation in Seniors with Heart Failure (SENIORS)
in 2128 patients aged 70 years and older with heart failure
independent of left ventricular ejection fraction at entry
demonstrated that nebivolol signiﬁcantly reduced the com-
posite outcome of all-cause mortality and cardiovascular
hospital admission by 14% but not the risk of all-cause
mortality compared with placebo.39 However, in a subgroup
of patients with low left ventricular ejection fraction (< 35%)
and a median age of 75 years, mortality was reduced by 38%,
showing similar results as those reported with other agents.
Cruickshank suggests that the ISA on the b2 and the b3 re-
ceptors is responsible for the reduction of effect on heart
failure with nebivolol.40 However, this is not supported by the
work of Brixius et al., showing that nebivolol seems devoid of
ISA in human myocardium.41Pharmacological Differences and Their Clinical
Implications
Cardioselectivity
By deﬁnition, b1/b2-selectivity, or cardioselectivity, rep-
resents the pharmacological characteristic of an agent that willpreferentially block b1 receptors, predominantly present in
the heart and renal juxtaglomerular apparatus, and conse-
quently have less inﬂuence on vascular smooth muscle and
bronchial b2 receptors. This feature possessed by many b-
blockers is of interest in clinical practice but the extent of
selectivity is not absolute and ranges widely among the
agents.42 Bisoprolol and nebivolol have the highest b1 selec-
tivity proﬁle compared with other b-blocking agents
commonly used.17 Of note, this clinical feature is inﬂuenced
by the magnitude of the dose and even cardioselective agents
can exert some inhibition of b2-receptors, at higher dosage
(equivalent to > 50 mg/d metoprolol).18
In terms of BP reduction, it seems that cardioselectivity
might inﬂuence the extent of the antihypertensive effect. In
fact, nonselective agents, by their blocking effect on b-2
vasodilatory receptors, might be less effective than car-
dioselective agents, those agents demonstrating less systolic BP
variability compared with nonselective agents.14 Bisoprolol 10
to 20 mg once daily has indeed been shown to lower BP more
effectively than atenolol 50 to 100 mg once daily, a moder-
ately cardioselective b-blocker.43 The Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT)44 examined 19,257 hy-
pertensive patients with at least 3 other risk factors and treated
with either an amlodipine-based treatment or an atenolol-
based treatment. Results favoured the amlodipine-based
treatment over atenolol for BP-lowering, metabolic effects,
and hard outcomes. A substudy of the ASCOT trial, the
Conduit Artery Function Evaluation (CAFE) trial,45 investi-
gated the effects of both study treatments on brachial and
central aortic pressures, ﬁnding that the amlodipine-based
therapy decreased central systolic pressure signiﬁcantly more
than the atenolol-based treatment, possibly contributing to
more strokes in the atenolol-based treatment group. A recent
Cochrane review concluded that, based on the literature
comparing b-blockers, especially atenolol, with placebo and
other classes of agents, the evidence does not support their use
as ﬁrst-line drugs in the treatment of hypertension.46 Car-
dioselectivity was not found to reduce aortic pulse pressure in
a recent study comparing bisoprolol with atenolol.47
Bronchial reactivity in asthma appears to be less enhanced
with more cardioselective b-blockers and is a concern with
nonselective agents.48 A meta-analysis demonstrated less
adverse respiratory effects in patients with “mild-to-moderate
reactive airway disease”,49 but reactive airways disease still
remains a limitation for the use of these agents in clinical
practice.
Vasodilation
In addition to their b1 receptor-blocking activity, third
generation b-blockers also exert their clinical effects through
vasodilatory properties. In Canada, labetalol and nebivolol are
indicated for the treatment of hypertension and carvedilol is
indicated for the treatment of heart failure. On a mechanistic
point of view, carvedilol and labetalol are vasodilatory through
a1-adrenoreceptor antagonism. Carvedilol has also been
associated with an increase in plasma levels of NO that occurs
through stimulation of NO synthase.50 Nebivolol has vaso-
dilatory properties through increased NO bioavailability,
which seems mainly responsible for its clinical effect.21 Others
have also suggested activation of b3 adrenoreceptors as a
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stimulation of endothelial NO synthase.51 These agents,
acting mainly through the reduction of peripheral vascular
resistance, have little or no effect on cardiac output.25
Vasodilatory b-blockers provide additional beneﬁts such as
reduced ventricular preload and afterload, improved renal
blood ﬂow, enhanced sodium secretion, and favourable effects
on myocardial cells.52 In contrast to traditional b-blockers
that do not reduce peripheral vascular resistance, vasodilatory
agents might provide beneﬁcial effects on endothelial
dysfunction, vascular remodelling, and progression of target
organ damage.52 Atenolol as an example, did not demonstrate
improvements in small artery structure and endothelial
function despite equal BP-lowering with calcium channel
blockers or angiotensin blockers, which did demonstrate im-
provements.53 Some of the rationale for lack of atenolol’s
effect included lack of effect on oxidative stress and peripheral
vasoconstriction.53 Two studies comparing nebivolol and
atenolol have shown that nebivolol has a more pronounced
effect on reducing aortic pulse pressure and wave reﬂection
and increasing pulse pressure ampliﬁcation.54,55 These effects
might be due to the associated vasodilation. Because stroke
risk is associated with higher central aortic pressure,56 vaso-
dilatory b-blockers might be more beneﬁcial than atenolol on
stroke protection. Whether this will actually translate into
additional beneﬁts in terms of morbidity/mortality end points
requires further investigation.
In the major clinical trials, b-blockers have been associated
with metabolic disturbances.57 As a class, they have been
associated with decreases in insulin sensitivity and an
increased incidence of new onset diabetes.57 Weight gain,
attenuation of the b receptor-mediated release of insulin from
pancreatic b-cells, and decreased blood ﬂow in skeletal muscle
tissue microcirculation are possible mechanisms leading to
decreased glucose uptake and increased insulin resistance.26
These data have come from studies involving traditional se-
lective or nonselective b-blockers, such as atenolol, metopro-
lol, and propranolol.58 A meta-analysis of 12 studies reporting
data on 94,492 patients has shown a 22% increased risk of
new-onset diabetes in patients treated with these 3 agents
compared with other classes of antihypertensive agents, with
the exception of the diuretic agents.58
Recent data emerging from the use of vasodilatory b-
blockers suggest that these agents might share neutral or even
beneﬁcial effects on metabolic parameters compared with more
traditional b-blockers. With regard to lipid abnormalities,
agents possessing vasodilatory properties such as carvedilol and
nebivolol seem to have a neutral or beneﬁcial effect on lipo-
protein lipase activity and levels of triglycerides and high-
density lipoprotein cholesterol, in contrast to more conven-
tional older b-blockers.20 With respect to glycemic effects, re-
sults from a study comparing atenolol with nebivolol in patients
with impaired glucose tolerance demonstrated that, compared
with baseline, atenolol induced a signiﬁcant reduction in insulin
sensitivity and in glucose disappearance rate as measured using a
euglycemic hyperinsulinemic clamp and nebivolol showed a
neutral effect on these parameters.59 Similarly, the Glycemic
Effects in Diabetes Mellitus: Carvedilol-Metoprolol Compari-
son in Hypertensives (GEMINI) study,60 which compared
metoprolol with carvedilol in 1235 patients with diabetes and
hypertension, showed that both treatments provided equivalentBP reduction but signiﬁcantly more patients in the metoprolol
group had to discontinue the study because of poor glycemic
control. Carvedilol, compared with metoprolol, improved
endothelial function and oxidative stress in patients with type 2
diabetes mellitus.61
Finally, some have suggested that vasodilatory b-blockers
might be better tolerated than nonvasodilatory agents. Studies
assessing quality of life suggested that agents such as nebivolol
might be as well tolerated as the angiotensin receptor blocker,
losartan.62 Among side effects negatively inﬂuencing patient
compliance, sexual dysfunction has been reported in up to
20% of patients receiving b-blockers.17 Nebivolol has been
associated with a signiﬁcant improvement in erectile function
compared with traditional b-blockers such as atenolol63 and
metoprolol.64 It seems that the NO-mediated vasodilatory
effects of nebivolol might contribute to sustained erectile
function.63,64
ISA
The b-blockers, acebutolol, labetalol, and pindolol, exhibit
ISA due to partial agonism at 1 or more b-adrenergic receptors.
Therefore, this property allows them to permit stimulation of
b-adrenoreceptors and blockade of sympathetic nervous system
signalling transmission.42 ISA has been shown to attenuate the
decrease in heart rate and cardiac output and the increase in
peripheral vascular resistance, respectively produced by the
blockade of the b1 and b2 receptors.65 Consequently, pos-
sessing this property might lessen antihypertensive efﬁcacy.
Hence, ISA does not seem to provide any advantage in patients
with CAD or hypertension because this pharmacologic prop-
erty has not been associated with any additional beneﬁts in
terms of outcomes. In this regard, a metaregression analysis has
shown that there was a near signiﬁcant trend toward a
decreased beneﬁt of agents with ISA in patients after an
MI.18,31 However, the Acebutolol et Prevention Secondaire de
l’Infarctus (APSI) trial has shown that acebutolol still decreases
mortality at 5 years in patients who had an MI.66
Lipophilicity/hydrophilicity
Lipophilic agents, such as propranolol, metoprolol, and
nebivolol67 have the ability to cross the blood-brain barrier.
Lipophilic agents are primarily eliminated by hepatic meta-
bolism and they tend to have shorter half-lives and wider
variations in plasma concentrations.18 Because of their hepatic
elimination, they are also generally more prone to clinically
signiﬁcant drug interactions. On the contrary, more hydro-
philic agents such as atenolol, sotalol, and nadolol are excreted
by the kidneys and therefore need to have their dosage adjusted
according to renal function.68 Sotalol in particular should be
used with caution in patients with low glomerular ﬁltration
rate (< 20 mL/min) because of the increased risk of torsade de
pointes.69 Because of central nervous system penetration,
lipophilic agents are frequently used for the treatment of
migraine and essential tremor.18 With regard to cardiovascular
protection, it has been suggested that lipophilic b-blockers
might have a different effect on hard end points such as
mortality, than hydrophilic agents. Indeed, it has been shown
that vagal tone, which has been associated with mortality,
might improve after penetration of central nervous system by
lipophilic agents.70 However, a study in 70,000 patients with
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important characteristic in preventing mortality.28
Lipophilic agents have commonly been identiﬁed as mol-
ecules with a poor tolerability proﬁle. Some have postulated
that the use of these agents might result in a greater incidence
of central nervous system effects such as lethargy, confusion,
and depression.68 A meta-analysis reporting results on more
than 35,000 patients from 15 different trials has shown that
b-blocker use was not associated with a signiﬁcant risk of
depressive symptoms but was associated with a small but
signiﬁcant risk of erectile dysfunction and fatigue.71
Regarding the risk of fatigue, the authors reported that it
was signiﬁcantly more frequent with early-generation b-
blockers (propranolol, timolol) compared with later-developed
agents. The degree of lipophilicity was not related to the
incidence of side effects.Who Should Receive b-Blockers in
Cardiovascular Medicine?
It remains quite clear that b-blocking agents with their
ability to block the b1-adrenergic receptor are the drugs of
choice in patients with acute or chronic cardiac ischemia.
They are also part of the treatment for patients with heart
failure in addition with a renin-angiotensin-aldosterone system
inhibition-based treatment. For the treatment of hypertension,
the Canadian Hypertension Education Program still recom-
mends their use as a ﬁrst-line option treatment in patients
younger than 60 years of age. However, when addressing the
question of the b-blockers place in therapy, the answer lies not
in global generalizations but in assessing individual patient
needs and speciﬁc b-blocking agent characteristics. Poor
tolerability often explains the reluctance of some clinicians to
recommend b-blockers to their patients. The new third-
generation b-blockers with a favourable tolerability proﬁle
might represent an alternative in patients presenting side effects
and necessitating the use of this cardiovascular class of agents.
Further studies are required to demonstrate the efﬁcacy of
these agents and their role in the clinician’s armamentarium.Funding Sources
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